Loading...
•
Jun 30
Outlook Therapeutics Q3 2025 Earnings Report
Outlook Therapeutics reported its first revenue from commercial sales in Europe and narrowed its adjusted net loss in Q3 2025.
Key Takeaways
Outlook Therapeutics posted $1.5M in revenue for Q3 2025 from initial European sales of LYTENAVA™, with a GAAP net loss of $20.2M. The company ended the quarter with $8.9M in cash and had 37M shares outstanding. The FDA PDUFA date for its lead asset is set for August 27, 2025.
First commercial revenue of $1.5M from sales of LYTENAVA™ in Germany and the UK
Net loss of $20.2M or $0.55 per share (GAAP), with adjusted loss of $15.8M or $0.44 per share
Cash and cash equivalents at quarter-end were $8.9M
Weighted average common shares outstanding was approximately 37M
Outlook Therapeutics
Outlook Therapeutics
Outlook Therapeutics Revenue by Geographic Location
Revenue by Geographic Location
Europe Revenue
CapyFin.com Forward Guidance
Outlook Therapeutics is preparing for potential FDA approval of ONS-5010 in August 2025 and ongoing commercial expansion in Europe.
Positive Outlook
- First commercial revenue generated in Europe
- FDA PDUFA decision expected by August 27, 2025
- Partnership with Cencora supports global commercialization
- Positive reception and patient dosing underway in Germany and UK
- Expanded manufacturing and regulatory readiness for U.S. launch
Challenges Ahead
- Net loss of $20.2M continues to reflect burn rate
- Cash position remains low at $8.9M
- Ongoing operating losses from R&D and SG&A expenses
- No guidance on U.S. pricing or market uptake
- Pending FDA decision still poses regulatory risk